IL6 and classic Hodgkin lymphoma: Based on our results, cHL patients in the high‐risk group with elevated levels of IL‐6 and LDH might have a poor prognosis, and these patients were not recommended to discontinue treatment even if they achieved 1‐year of sustained CR.